Table 2.
Enriched Biological Functions of the Top 20 Most Positively Perturbed Genes Leading to the Target Condition Heart-Left Ventricle
| Term Category | Enriched Terms | First Hit Term Description | q Value |
|---|---|---|---|
| Coexpression | 933 | rat breast_Giusti09_300genes | 1.72 × 10−25 |
| Coexpression | 985 | heart muscle | 8.01 × 10−22 |
| Computational | 315 | neighborhood of MYL2 | 5.29 × 10−22 |
| Disease | 969 | cardiomyopathy, familial idiopathic | 1.47 × 10−9 |
| Drug | 1522 | doxorubicin | 2.88 × 10−11 |
| Gene family | 22 | F-type ATPases|mitochondrial complex V | 2.28 × 10−11 |
| GO: BP | 3311 | striated muscle contraction | 2.01 × 10−15 |
| GO: CC | 852 | sarcomere | 2.53 × 10−15 |
| GO: MF | 225 | structural constituent of muscle | 8.08 × 10−6 |
| Phenotype | 867 | sudden death (human) | 2.04 × 10−7 |
| Interaction | 280 | VDAC1 interactions | 1.94 × 10−5 |
| MicroRNA | 1 | Hsa-miR-610:mirSVR | 3.77 × 10−5 |
| Phenotype | 1419 | cardiac hypertrophy (mouse) | 2.47 × 10−9 |
| Pathway | 1340 | cardiac muscle contraction | 4.01 × 10−14 |
| PubMed | 10,774 | clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. | 1.13 × 10−19 |
| ToppCell Atlas | 209 | mouse multiple adult muscle | 2.90 × 10−18 |
| subtype heart_cardiac muscle cell | |||
| TFBS | 21 | V$MEF2_02 | 8.40 × 10−6 |